NASDAQ:ALDR - Alder Biopharmaceuticals Price Target & Analyst Ratings

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

9 Wall Street analysts have issued ratings and price targets for Alder Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $17.7143, suggesting that the stock has a possible upside of 91.09%. The high price target for ALDR is $21.00 and the low price target for ALDR is $14.00. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

Alder Biopharmaceuticals (NASDAQ:ALDR) Consensus Price Target History

Alder Biopharmaceuticals (NASDAQ:ALDR) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
7/10/2019	Credit Suisse Group	Reiterated Rating	Neutral		Medium
5/28/2019	Svb Leerink	Initiated Coverage	Outperform ➝ Outperform		High
5/28/2019	Leerink Swann	Initiated Coverage	Outperform	$21.00	Medium
5/3/2019	Cowen	Set Price Target	Buy	$18.00	Low
5/3/2019	Mizuho	Reiterated Rating	Hold	$15.00	High
5/2/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$14.00	High
3/14/2019	Canaccord Genuity	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00	High
11/6/2018	Wells Fargo & Co	Initiated Coverage	Outperform		Medium
9/10/2018	Morgan Stanley	Initiated Coverage	Underweight ➝ Underweight	$19.00	High
8/8/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Buy	$21.00 ➝ $23.00	Low
8/7/2018	Stifel Nicolaus	Initiated Coverage	Buy	$30.00	Low
8/6/2018	Piper Jaffray Companies	Initiated Coverage	Overweight	$28.00	Low
6/27/2018	Needham & Company LLC	Initiated Coverage	Buy	$28.00	High
4/24/2018	Goldman Sachs Group	Initiated Coverage	Neutral	$17.00	High
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$17.00	High

(Data available from 8/22/2017 forward)